Overseas revenue plummets, dragging down performance; the fundraising projects of Ota Biotechnology are delayed.

① Due to the impact of international situations, economic policies, and fluctuations in the overall market, the fundraising projects of Aotai Biological aimed at expanding overseas markets will be delayed. ② Overseas revenue has always been the most core source of income for Aotai Biological, with the overall income proportion once reaching 99.83%, and the sharp decline in overseas revenue has also led to a significant drop in Aotai Biological's overall income.

cls.cnDec 26 03:37 ET

The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.

According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.

cls.cnDec 25 19:09 ET

It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17 09:51 ET

TGA Annual Best Action Game Award! "Black Myth: Wukong" sets a new milestone for Chinese gaming.

① On December 13, China's first 3A game "Black Myth: Wukong" won TGA's "Game of the Year" award and the "Players' Voice Award"; ② The game, developed by Game Science, is inspired by "Journey to the West" and has received widespread praise for its graphics, combat system, and storytelling; ③ "Black Myth" was nominated for four awards at TGA and won the 2024 Golden Joystick Award for "Game of the Year" among other awards.

cls.cnDec 13 00:13 ET

When will Hunan Nucien Pharmaceutical Co., Ltd. emerge from the shadow of losses after the termination and delay of core Innovative Drugs projects?

① Due to the high difficulty and slow progress of research and development, Hunan Nucien Pharmaceutical Co., Ltd. has terminated the development of the paramivir powder inhalation project. Additionally, due to stricter approval processes, the paramivir inhalation solution project will be postponed for two years. ② In the face of competition for paramivir injection, the adjustment of new drug projects will bring new uncertainties to the development of Hunan Nucien Pharmaceutical Co., Ltd.

cls.cnDec 12 03:11 ET

In the midst of competition, can CanSino Biologics Inc. provide a satisfactory answer to the market?|Focus

① In the next three years, CANSINOBIO will primarily focus on the vaccine market for infants aged 0-6; ② Furthermore, CANSINOBIO will continue to deepen its expansion into overseas markets. Currently, the company has established stable and long-term Global Strategy partnerships with partners in target markets such as Southeast Asia and the Middle East, while also expanding the Global vaccine supply system through cooperation with international organizations and multiple governments.

cls.cnDec 10 05:18 ET